Human Mesenchymal Stem Cells: The Art to Use Them in the Treatment of Previously Untreatable

Lakota, Ján; Dubrovčáková, Mária; Haider, Khawaja Husnain

doi:10.1007/978-981-16-6016-0_1-1

Cited by 15 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 The use of allogeneic MSCs offers numerous logistical advantages: surgical intervention is no longer required to obtain the starting material, and the quality of the final preparations can be better controlled. 40 In this study, 25×10 6 MSCs were inserted into each submandibular gland and 50×10 6 MSCs were inserted into each parotid gland in ten patients; the follow-up period was four months. During this period, an increase in mean unstimulated salivary flow was measured from an initial 0.13 ml/min to 0.18 ml/min.…”

Section: Discussionmentioning

confidence: 99%

Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial

Strojan,

Plavc,

Kokalj

et al. 2023

Radiology and Oncology

View full text Add to dashboard Cite

Background Xerostomia is a common side effect of radiotherapy in patients with head and neck tumors that negatively affects quality of life. There is no known effective standard treatment for xerostomia. Here, we present the study protocol used to evaluate the safety and preliminary efficacy of allogeneic mesenchymal stromal stem cells (MSCs) derived from umbilical cord tissue. Patients and methods Ten oropharyngeal cancer patients with post-radiation xerostomia and no evidence of disease recurrence 2 or more years after (chemo)irradiation (intervention group) and 10 healthy volunteers (control group) will be enrolled in this nonrandomized, open-label, phase I exploratory study. MSCs from umbilical cord tissue will be inserted under ultrasound guidance into both parotid glands and both submandibular glands of the patients. Toxicity of the procedure will be assessed according to CTCAE v5.0 criteria at days 0, 1, 5, 28, and 120. Efficacy will be assessed by measuring salivary flow and analyzing its composition, scintigraphic evaluation of MSC grafting, retention, and migration, and questionnaires measuring subjective xerostomia and quality of life. In addition, the radiological, functional, and morphological characteristics of the salivary tissue will be assessed before, at 4 weeks, and at 4 months after the procedure. In the control group subjects, only salivary flow rate and salivary composition will be determined. Discussion The use of allogeneic MSCs from umbilical cord tissue represents an innovative approach for the treatment of xerostomia after radiation. Due to the noninvasive collection procedure, flexibility of cryobanking, and biological advantages, xerostomia therapy using allogeneic MSCs from umbilical cord tissue may have an advantage over other similar therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial

Strojan,

Plavc,

Kokalj

et al. 2023

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…Several studies reveal that MSCs may display immunosuppressive or immunomodulatory properties 43,51,[52][53][54][55] . MSCs also tend to reduce the effects of b inflammatory and protect against the Cytokine Storm.…”

Section: Mscs In Relation To Neuroinflammationmentioning

confidence: 99%

Untitled

2022

IJPSR

View full text Add to dashboard Cite

Mesenchymal Stem Cells are multipotent adult stem cells that are found in tissues of the body, including umbilical lines, bone marrow, fat cells, etc. Mesenchymal stem cells incline to self-restore tissues, such as bone, fat cells, connective tissues, and microglia cells, which are obtained from the mesoderm layer and act as macrophages in the central nervous system. So, MSCs can be used to promote functional recovery in many neurological disorders. Neuroinflammation is a pathological feature of neurodegenerative diseases, which is also indicated to mediate neuronal damage and deteriorate the backward accumulation of Aβ in Alzheimer's disease. The mechanism for MSC-based therapy in Alzheimer's disease that MSCs regulate neuroinflammation by microglia activation; this will reduce pathological features such as tau hyperphosphorylation and Aβ deposits and save the spatial learning and memory deficits and their multipotentiality and secretome, based on these findings include cell therapy methods for Parkinson disease mainly focused on the ability of stem cells to differentiate into Dopaminergic neurons producing cells that will replace diseased Dopaminergic neurons. MSC-based therapeutics have been suggested for osteoarthritis. MSCs were mostly found in a thin layer of connective tissue called periosteum, lungs, milk teeth, tendon, synovial stratum, cancellous bone, adipose tissue, tendon, lung, and other tissues. MSCs associated with immune cells and have immunomodulatory effects. Moreover, the RAP1/NFkb signalling pathway controls MSC paracrine activity, which seems to be linked with Female infertility. This review will assist you in understanding many aspects of MSC and its molecular role and therapeutic applications.

show abstract